Expression and prognosis analysis of TET family in acute myeloid leukemia
Figure 4.The impact of TET3 expression on overall survival of AML patients. (A–D) Two independent cohorts of 162 and 78 cytogenetically normal AML (CN-AML) patients were obtained from Gene Expression Omnibus (GEO) data (http://www.ncbi.nlm.nih.gov/geo/; accession number GSE12417). Survival analysis was performed through the online web tool Genomicscape (http://genomicscape.com/microarray/survival.php). (A) probe 214754_at (TET3) in 78 CN-AML patients; (B) probe 235542_at (TET3) in 78 CN-AML patients; (C) probe 214754_at (TET3) in 162 CN-AML patients; (D) probe 235542_at (TET3) in 162 CN-AML patients.